A multinational, randomized, placebo-controlled, double-blind, phase III trial using antithrombin III and rhTM was conducted to investigate their efficacy and safety in adult patients with sepsis and coagulopathy (34, 35); however, the absolute risk of 28-day mortality did not reach statistical significance (34). The gene discussed is SERPINC1; the disease is blood coagulation disease.